Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) (American Psychiatric Association, Washington, DC, 2013).
Barbaresi, W. J. et al. Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. Pediatrics 131, 637–644. https://doi.org/10.1542/peds.2012-2354 (2013).
Biederman, J., Petty, C. R., Clarke, A., Lomedico, A. & Faraone, S. V. Predictors of persistent ADHD: an 11-year follow-up study. J. Psychiatr. Res. 45, 150–155. https://doi.org/10.1016/j.jpsychires.2010.06.009 (2011).
Cheung, C. H. M. et al. Childhood predictors of adolescent and young adult outcome in ADHD. J. Psychiatr. Res. 62, 92–100. https://doi.org/10.1016/j.jpsychires.2015.01.011 (2015).
Lara, C. et al. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol. Psychiatry 65, 46–54. https://doi.org/10.1016/j.biopsych.2008.10.005 (2009).
Harpin, V. A. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch. Dis. Child. 90(Suppl 1), i2-7. https://doi.org/10.1136/adc.2004.059006 (2005).
Hoza, B. et al. What aspects of peer relationships are impaired in children with attention-deficit/hyperactivity disorder?. J. Consult. Clin. Psychol. 73, 411–423. https://doi.org/10.1037/0022-006x.73.3.411 (2005).
Saito, M. Japanese Guideline for Diagnosis and Treatment of AD/HD 4th edn. (Jiho, Tokyo, 2016) (in Japanese).
Miyachi, T. et al. The investigation into the actual conditions of medication for the child with attention deficit/hyperactivity disorder (AD/HD) in Japan. Psychiatr. Neurolo. Paediatr. Jpn. 50, 419–427 (2010) (in Japanese).
Kimura, S., Sato, T., Ikeda, S., Noda, M. & Nakayama, T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J. Epidemiol. 20, 413–419. https://doi.org/10.2188/jea.je20090066 (2010).
Barner, J. C., Khoza, S. & Oladapo, A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr. Med. Res. Opin. 27(Suppl 2), 13–22. https://doi.org/10.1185/03007995.2011.603303 (2011).
Brinkman, W. B., Sucharew, H., Majcher, J. H. & Epstein, J. N. Predictors of medication continuity in children with ADHD. Pediatrics 141, e20172580. https://doi.org/10.1542/peds.2017-2580 (2018).
Faraone, S. V., Biederman, J. & Zimmerman, B. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD. J. Atten. Disord. 11, 157–166. https://doi.org/10.1177/1087054706295663 (2007).
Gau, S.S.-F. et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J. Clin. Psychiatry 69, 131–140. https://doi.org/10.4088/jcp.v69n0118 (2008).
Sanchez, R. J., Crismon, M. L., Barner, J. C., Bettinger, T. & Wilson, J. P. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 25, 909–917. https://doi.org/10.1592/phco.2005.25.7.909 (2005).
Thiruchelvam, D., Charach, A. & Schachar, R. J. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 40, 922–928. https://doi.org/10.1097/00004583-200108000-00014 (2001).
Marcus, S. C., Wan, G. J., Kemner, J. E. & Olfson, M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch. Pediatr. Adolesc. Med. 159, 572–578. https://doi.org/10.1001/archpedi.159.6.572 (2005).
Visser, S. N., Lesesne, C. A. & Perou, R. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics 119(Suppl 1), S99-106. https://doi.org/10.1542/peds.2006-2089O (2007).
Storebø, O. J. et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents—assessment of adverse events in non-randomised studies. Cochrane Database Syst. Rev. 5, CD012069. https://doi.org/10.1002/14651858.CD012069.pub2 (2018).
Swanson, J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs 17, 117–131. https://doi.org/10.2165/00023210-200317020-00004 (2003).
Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/800155_1179009G1022_1_17. Accessed Jan 2021.
Statistics_Bureau_of_Japan. Japanese Population on the First Day of Every Month. https://www.stat.go.jp/data/jinsui/2.html#monthly. Accessed Jan 2021.
Ching, C., Eslick, G. D. & Poulton, A. S. Evaluation of methylphenidate safety and maximum-dose titration rationale in attention-deficit/hyperactivity disorder: a meta-analysis. JAMA Pediatr. 173, 630–639. https://doi.org/10.1001/jamapediatrics.2019.0905 (2019).
Razani, N. et al. Neighborhood characteristics and ADHD: results of a national study. J. Atten. Disord. 19, 731–740. https://doi.org/10.1177/1087054714542002 (2015).
Lash, T. L. Applying Quantitative Bias Analysis to Epidemiologic Data (Springer, Berlin, 2009).
Bachmann, C. J. et al. Trends in ADHD medication use in children and adolescents in five western countries, 2005–2012. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 27, 484–493. https://doi.org/10.1016/j.euroneuro.2017.03.002 (2017).
McCarthy, S. et al. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr. 12, 78. https://doi.org/10.1186/1471-2431-12-78 (2012).
Stephenson, C. P., Karanges, E. & McGregor, I. S. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Aust. N. Zeal. J. Psychiatry 47, 74–87. https://doi.org/10.1177/0004867412466595 (2013).
Zuvekas, S. H. & Vitiello, B. Stimulant medication use in children: a 12-year perspective. Am. J. Psychiatry 169, 160–166. https://doi.org/10.1176/appi.ajp.2011.11030387 (2012).
Okumura, Y. et al. Prevalence, incidence and persistence of ADHD drug use in Japan. Epidemiol. Psychiatr. Sci. 28, 692–696. https://doi.org/10.1017/s2045796018000252 (2019).
Burcu, M., Zito, J. M., Metcalfe, L., Underwood, H. & Safer, D. J. Trends in stimulant medication use in commercially insured youths and adults, 2010–2014. JAMA Psychiatry 73, 992–993. https://doi.org/10.1001/jamapsychiatry.2016.1182 (2016).
Karlstad, Ø., Furu, K., Stoltenberg, C., Håberg, S. E. & Bakken, I. J. ADHD treatment and diagnosis in relation to children’s birth month: Nationwide cohort study from Norway. Scand. J. Public Health 45, 343–349. https://doi.org/10.1177/1403494817708080 (2017).
Beau-Lejdstrom, R., Douglas, I., Evans, S. J. W. & Smeeth, L. Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence. BMJ Open 6, e010508. https://doi.org/10.1136/bmjopen-2015-010508 (2016).
Kovess, V. et al. Psychotropic medication use in French children and adolescents. J. Child Adolesc. Psychopharmacol. 25, 168–175. https://doi.org/10.1089/cap.2014.0058 (2015).
Piovani, D., Clavenna, A., Cartabia, M. & Bonati, M. Psychotropic medicine prescriptions in Italian youths: a multiregional study. Eur. Child Adolesc. Psychiatry 25, 235–245. https://doi.org/10.1007/s00787-015-0726-0 (2016).
Bachmann, C. J., Philipsen, A. & Hoffmann, F. ADHD in Germany: trends in diagnosis and pharmacotherapy. Dtsch. Arztebl. Int. 114, 141–148. https://doi.org/10.3238/arztebl.2017.0141 (2017).
Bolea-Alamañac, B. et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. (Oxford) 28, 179–203. https://doi.org/10.1177/0269881113519509 (2014).
Kooij, S. J. J. et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry 10, 67. https://doi.org/10.1186/1471-244x-10-67 (2010).
National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. https://www.nice.org.uk/guidance/ng87 (2019).
Cortese, S. et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5, 727–738. https://doi.org/10.1016/s2215-0366(18)30269-4 (2018).
Liu, Q., Zhang, H., Fang, Q. & Qin, L. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials. J. Clin. Exp. Neuropsychol. 39, 854–865. https://doi.org/10.1080/13803395.2016.1273320 (2017).
Howland, R. H. Medication holidays. J. Psychosoc. Nurs. Ment. Health Serv. 47, 15–18. https://doi.org/10.3928/02793695-20090804-01 (2009).
Hodgkins, P., Sasane, R., Christensen, L., Harley, C. & Liu, F. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Curr. Med. Res. Opin. 27(Suppl 2), 53–62. https://doi.org/10.1185/03007995.2011.623158 (2011).
Lachaine, J., Beauchemin, C., Sasane, R. & Hodgkins, P. S. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. Postgrad. Med. 124, 139–148. https://doi.org/10.3810/pgm.2012.05.2557 (2012).
Marcus, S. C. & Durkin, M. Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 50, 480–489. https://doi.org/10.1016/j.jaac.2011.02.007 (2011).
Rucklidge, J. J. Gender differences in attention-deficit/hyperactivity disorder. Psychiatr. Clin. N. Am. 33, 357–373. https://doi.org/10.1016/j.psc.2010.01.006 (2010).
Cornforth, C., Sonuga-Barke, E. & Coghill, D. Stimulant drug effects on attention deficit/hyperactivity disorder: a review of the effects of age and sex of patients. Curr. Pharm. Des. 16, 2424–2433. https://doi.org/10.2174/138161210791959827 (2010).
Katzman, M. A. & Sternat, T. A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder. CNS Drugs 28, 1005–1033. https://doi.org/10.1007/s40263-014-0175-1 (2014).
Storebø, O. J. et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ 351, h5203. https://doi.org/10.1136/bmj.h5203 (2015).
Treuer, T. et al. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J. Child Adolesc. Psychopharmacol. 23, 179–193. https://doi.org/10.1089/cap.2012.0093 (2013).
Hvolby, A. Associations of sleep disturbance with ADHD: implications for treatment. Atten. Defic. Hyperact. Disord. 7, 1–18. https://doi.org/10.1007/s12402-014-0151-0 (2015).
Martins, R. et al. Sleep disturbance in children with attention-deficit hyperactivity disorder: a systematic review. Sleep Sci. 12, 295–301. https://doi.org/10.5935/1984-0063.20190088 (2019).
Wajszilber, D., Santiseban, J. A. & Gruber, R. Sleep disorders in patients with ADHD: impact and management challenges. Nat. Sci. Sleep 10, 453–480. https://doi.org/10.2147/nss.S163074 (2018).
Corkum, P. et al. The effects of extended-release stimulant medication on sleep in children with ADHD. J. Can. Acad. Child Adolesc. Psychiatry 29, 33–43 (2020).
Kidwell, K. M., Van Dyk, T. R., Lundahl, A. & Nelson, T. D. Stimulant medications and sleep for youth with ADHD: a meta-analysis. Pediatrics 136, 1144–1153. https://doi.org/10.1542/peds.2015-1708 (2015).